VAERS Explorer
Back to explore

Report #2889451

Received Mar 18, 2026

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Female
Age
Age unknown
State
Recovered
Unknown
Vaccinated
Mar 20, 2025
Onset
Days to onset
Hospital days

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
TYPTYPHOID LIVE ORAL TY21A (VIVOTIF)BERNA BIOTECH, LTD.1unknownPO / MO

Symptoms (1)

Product administration error

Symptom narrative

The patient took first dose of Vivotif with food; Case reference number US-BN-2025-000394 is a spontaneous case initially received from nurse via Communication (reference number: USBAV25-0642) on 20-Mar-2025 and concerns a 75-year-old, female patient. The patient's medical history and concomitant medication details were not provided. On 20-Mar-2025, the patient took the first dose of Vivotif with food (batch number: unknown), orally, at dose of one capsule, for indication typhoid fever immunization (explicitly coded as 'product administration error'). At the time of the initial report, it was unknown if the patient experienced any of adverse events due to Vivotif. No further information was provided.; Reporter's Comments: A 75-year-old, female patient took the first dose of Vivotif with food, orally, at dose of one capsule, for indication typhoid fever immunization which is considered as product administration error. Product administration error is considered listed per company convention. At this point, it was unknown if the patient experienced any of adverse events due to Vivotif. The patient's medical history and concomitant medication details were not provided. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.; Sender's Comments: A 75-year-old, female patient took the first dose of Vivotif with food, orally, at dose of one capsule, for indication typhoid fever immunization which is considered as product administration error. Product administration error is considered listed per company convention. At this point, it was unknown if the patient experienced any of adverse events due to Vivotif. The patient's medical history and concomitant medication details were not provided. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.

Medical history

Comments: NONE